BioPharma Dive April 4, 2024
Kristin Jensen

After years of ups and downs, Swiss drugmaker Basilea has broken into the U.S. market with its drug Zevtera, but is still searching for a partner.

Dive Brief:

  • Swiss drugmaker Basilea Pharmaceutica on Wednesday won Food and Drug Administration approval for its drug Zevtera in a step that could help address the critical need for new antibiotics in the U.S.
  • The FDA cleared the drug for three different conditions: community-acquired bacterial pneumonia, Staphylococcus aureus bloodstream infections, and acute bacterial skin and skin structure infections. The approval covers adults with any of the three conditions as well as pediatric patients with pneumonia.
  • Basilea plans to announce a commercial partner for the U.S. market “around mid-year” and said interest increased as...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA Approves First Biosimilar of Xolair
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article